



Mobidiag Appoints Joseph Bernardo as Senior Strategic Advisor

ESPOO, Finland, December 10, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the appointment of Joseph E. Bernardo as Senior Strategic Advisor to the Company.

Mr. Bernardo has over twenty years of experience in the diagnostics industry including a significant tenure as a President at Thermo Fisher Scientific, working across a number of divisions including Clinical Next-Generation Sequencing and Oncology, Immuno-Diagnostics, Anatomic Pathology and Fisher HealthCare, the hospital laboratory distribution business of Thermo Fisher.

Prior to joining Thermo Fisher Mr. Bernardo held roles at Siemens Medical Solutions Diagnostics, culminating as Senior Vice President and GM of the Company's Central Laboratory Business Unit and as an Area Director at Abbott Laboratories.

Mr. Bernardo is currently Chairman of the Board of Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics. He is also an Operating Partner at Linden Capital Partners, a Chicago-based private equity group focused exclusively on leveraged investments in middle market healthcare and life science companies. He was previously Chairman of SeraCare Life Sciences, Inc., a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, which was sold to LGC in November 2018.

Tuomas Tenkanen, CEO of Mobidiag, said: "We are pleased to welcome Joe as a Senior Strategic Advisor to Mobidiag. He brings with him a vast amount of experience gained at some of the world's leading diagnostic companies and has a proven track record across the total diagnostic value chain, from R&D to marketing. His strategic insight and intimate knowledge of the industry will be invaluable to us as we continue our journey towards becoming a leading player in the molecular diagnostics market, providing innovative and differentiated solutions that are adopted by laboratories across Europe."

Contacts

Johanna Sarapää, Marketing Communications
+358 10 2054 771
marketing@mobidiag.com

Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com

Notes to editors

About Mobidiag Ltd

Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adaptability for large scale manufacturing, Mobidiag's Amplidiag® and Novodiag® platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company's highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag's initial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.

Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com